International Stem Cell Corporation is currently running a Phase I clinical trial using human parthenogenetic stem cell-derived neural stem cells (ISC-hpNSC®). The company, through its wholly-owned Australian subsidiary, Cyto Therapeutics, is currently enrolling patients for the treatment of moderate to severe Parkinson’s disease in Melbourne, Victoria, Australia at the Department of Neurology of the Royal Melbourne Hospital.
If anyone participates please keep us posted!